LIlly comes on board at think tank

Share this article:
Eli Lilly
Eli Lilly

National Pharmaceutical Council (NPC) said Eli Lilly joined earlier this year. NPC conducts research on topics like the challenges of individual patient treatment effects, utilization of real-world evidence and comparative effectiveness research.

In a statement, Mark Nagy, Lilly VP, global patient outcomes and real world evidence, said, “With the full implementation of the Affordable Care Act, access to healthcare and medicines is becoming a reality for more Americans, while at the same time the personalization of drug treatments is beginning to become a reality. These changes are sparking new conversations and challenges, and I look forward to working with NPC to address them.”

Nagy will serve as Lilly's representative on the NPC board of directors.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?